Protocol Ledger

NCT04044170 · Phase II · TERMINATED

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Interventional Phase II clinical trial protocol NCT04044170 sponsored by Hanmi Pharmaceutical Company Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-30 Enrollment: 5 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04044170
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)5 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04044170
Protocol FieldVerified Registry Value
NCT IdentifierNCT04044170
Consolidated Lead SponsorHanmi Pharmaceutical Company Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment5 participants (ACTUAL)
Registered Start Date2019-07-30
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04044170
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
Cancer Hospital Chinese Academy of Medical SciencesBeijing, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI